Cargando…

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib

The third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) osimertinib is approved for untreated, or previously EGFR‐TKI–treated T790M‐positive EGFR‐mutated non‐small cell lung carcinoma (NSCLC). We investigated the heterogeneity of responses to osimertinib and its un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishiyama, Akihiro, Takeuchi, Shinji, Adachi, Yuta, Otani, Sakiko, Tanimoto, Azusa, Sasaki, Motoko, Matsumoto, Shingo, Goto, Koichi, Yano, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Drug Discovery and Delivery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540985/ https://www.ncbi.nlm.nih.gov/pubmed/32735723 http://dx.doi.org/10.1111/cas.14593

Ejemplares similares

Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine
por: Komoto, Kana, et al.
Publicado: (2020)

dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells
por: Yokogawa, Tatsushi, et al.
Publicado: (2020)

Effect of murine double‐minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys
por: Kawata, Yoshiko, et al.
Publicado: (2020)

Trametinib overcomes KRAS‐G12V–induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2021)

Baicalein inhibits non‐small‐cell lung cancer invasion and metastasis by reducing ezrin tension in inflammation microenvironment
por: Zhang, Xiaolong, et al.
Publicado: (2020)

Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells
por: Ohgino, Keiko, et al.
Publicado: (2020)

Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2020)

ROS Modulating Inorganic Nanoparticles: A Novel Cancer Therapeutic Tool
por: Newton Amaldoss, Maria John, et al.
Publicado: (2022)

Recent Patents on Nasal Vaccines Containing Nanoadjuvants
por: Candela, Francesco, et al.
Publicado: (2022)

Optimizing and Evaluating the Transdermal Permeation of Hydrocortisone Transfersomes Formulation Based on Digital Analysis of the In Vitro Drug Release and Ex Vivo Studies
por: Abdelwahd, Asmae, et al.
Publicado: (2022)

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
por: Adachi, Yuta, et al.
Publicado: (2020)

Osimertinib-induced Keratitis and Secondary Toxic Epidermal Necrotic Drug Eruption- A Case Report and Literature Review
por: Xu, Yunhua, et al.
Publicado: (2023)

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
por: Niwa, Hideyuki, et al.
Publicado: (2018)

Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging)
por: Huang, Chen, et al.
Publicado: (2023)

Standardised evaluation of medicine acceptability in paediatric population: reliability of a model
por: Vallet, Thibault, et al.
Publicado: (2017)

Evaluation of comparative soft tissue response to bone void fillers with antibiotics in a rabbit intramuscular model
por: Oliver, Rema A, et al.
Publicado: (2019)

The Application of Failure Modes and Effects Analysis Methodology to Intrathecal Drug Delivery for Pain Management
por: Saulino, Michael F., et al.
Publicado: (2016)

Exogenous Surfactant as a Pulmonary Delivery Vehicle for Budesonide In Vivo
por: Baer, Brandon, et al.
Publicado: (2020)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

DDEL-02. DECREASED TOXICITY OF CONVENTIONAL DOSE CHEMOTHERAPY UTILIZING BODY WEIGHT INSTEAD OF BODY SURFACE AREA FOR DOSING IN YOUNG CHILDREN <6 YEARS OLD ENROLLED ON THE “HEAD START” 4 CLINICAL TRIAL
por: Dhall, Girish, et al.
Publicado: (2020)

DDEL-12. NANOPARTICLE DELIVERY OF DOXORUBICIN FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Ung, Caitlin, et al.
Publicado: (2020)

DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS
por: Stepien, Natalia, et al.
Publicado: (2020)

DDEL-15. NANOTHERAPEUTIC TARGETING OF TUMOR ENDOTHELIUM FOR ENHANCING DRUG DELIVERY PAST THE BLOOD-BRAIN BARRIER
por: Kiguchi, Hiro, et al.
Publicado: (2020)

DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Sasaki, Takahiro, et al.
Publicado: (2020)

DDEL-13. FOCUSED ULTRASOUND MEDIATED BLOOD BRAIN BARRIER DISRUPTION IN A MURINE MODEL OF PONTINE GLIOMA: A SAFETY AND FEASIBILITY STUDY
por: Englander, Zachary, et al.
Publicado: (2020)

DDEL-06. DRUG INTERACTION BETWEEN EVEROLIMUS AND CANNABIDIOL IN PEDIATRIC PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: A SINGLE INSTITUTION EXPERIENCE
por: Sabus, Ashley, et al.
Publicado: (2020)

DDEL-01. ENHANCING DRUG DELIVERY WITH MRgFUS FOR DIFFUSE INTRINSIC PONTINE GLIOMA MODEL
por: Ishida, Joji, et al.
Publicado: (2020)

DDEL-08. CONVECTION-ENHANCED DELIVERY OF NIMUSTINE HYDROCHLORIDE (ACNU) AGAINST PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMAS
por: Saito, Ryuta, et al.
Publicado: (2020)

DDEL-09. HIGH DOSE MTX110 (SOLUBLE PANOBINOSTAT) SAFELY ADMINISTERED INTO THE FOURTH VENTRICLE IN A NON-HUMAN PRIMATE MODEL
por: Sirianni, Rachael W, et al.
Publicado: (2020)

DDEL-16. UNDERSTANDING OPTIMAL CONVECTION-ENHANCED DELIVERY PHYSICO-CHEMICAL INFUSION PARAMETERS: THE ROLE OF BBB EFFLUX PUMPS IN DRUG DISTRIBUTION AND CLEARANCE
por: Power, Erica, et al.
Publicado: (2020)

DDEL-17. TRIPLE INTRAVENTRICULAR CHEMOTHERAPY FOR TREATMENT OF RELAPSED CHOROID PLEXUS CARCINOMA
por: Lau, Grace, et al.
Publicado: (2020)

DDEL-04. ENGINEERED NANOCARRIERS TO ENHANCE DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER
por: Straehla, Joelle P, et al.
Publicado: (2020)

DDEL-14. SAFETY OF INTERVENTRICULAR METHOTREXATE ADMINISTRATION FOLLOWING RADIATION IN PEDIATRIC PATIENTS WITH MALIGNANT BRAIN TUMORS
por: Rosales, Kristofer, et al.
Publicado: (2020)

DDEL-05. BLOOD-BRAIN BARRIER DISRUPTION AND ENHANCED RADIOSENSITIZERS EXTRAVASATION UPON FOCUSED ULTRASOUND FOR TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Hart, Elvin ‘t, et al.
Publicado: (2020)

DDEL-07. A PHASE I STUDY EXAMINING THE FEASIBILITY OF INTERMITTENT CONVECTION-ENHANCED DELIVERY (CED) OF MTX110 FOR THE TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED DIFFUSE MIDLINE GLIOMAS
por: Zacharoulis, Stergios, et al.
Publicado: (2020)

Targeted Drug Delivery for Chronic Nonmalignant Pain: Longitudinal Data From the Product Surveillance Registry
por: Schultz, David M., et al.
Publicado: (2021)

Short‐Term Outcomes of a High‐Volume, Low‐Concentration Bolus Starting Dose Technique With Ziconotide: A Case Series
por: Lindley, David
Publicado: (2021)

Isotopic Scintigraphy in Intrathecal Drug Delivery Failure: A Single‐Institution Case Series
por: Delhaas, Elmar M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qb4rl3rpva0i8b1bl9abe9q1t5